BridgeBio has a marketed drug and three FDA dates in seven months

The technology

BridgeBio is a rare-disease company built around small-molecule drugs aimed at the biology of genetic conditions. Its one marketed product is acoramidis, sold as Attruby in the U.S., a near-complete TTR stabilizer for ATTR-CM, a form of heart failure. The pipeline follows the same logic. Infigratinib blocks the overactive FGFR3 receptor behind achondroplasia. Encaleret blocks the overactive calcium-sensing receptor in ADH1. BBP-418 gives a partly working enzyme more substrate in LGMD2I/R9.

All four are oral. In achondroplasia, the incumbent is BioMarin's Voxzogo, a CNP analogue that reported $253 million of second-quarter sales.

The odds

Three FDA decisions sit inside seven months. BBP-418 has a Nov 27, 2026 date, infigratinib has Feb 4, 2027, and encaleret has May 8, 2027. All three have Priority Review and none has an advisory committee planned.

The published base rates are encouraging. In the BIO/Informa/QLS 2011 to 2020 study, 90.6% of applications reached approval, and 93.6% in rare disease. Those are averages, and each file has its own quirks. Infigratinib has the cleanest data: a randomized phase 3 with a 1.74 cm per year gain over placebo on its primary endpoint. Encaleret's file rests on calcium endpoints, with symptom data that are patient-reported. BBP-418's cardiac data are exploratory, and how the FDA reads the biomarker data is the open question.

Beyond the filings, the next phase 3 is RECLAIM-HP in chronic hypoparathyroidism, with topline data guided to late 2027 or early 2028. The same study put phase 3 to filing success at 60.4% for rare disease, so that is a genuine risk and a larger market.

The money

Attruby sales were $222.4 million in the second quarter, up from $71.5 million a year earlier, on total revenue of $243.7 million. The company still lost $152.2 million attributable to common holders in the quarter. Cash and marketable securities were $720.2 million on June 30, before a $1 billion preferred equity deal that closed July 1 with $933.9 million funded at close.

The preferred carries a 7% dividend, payable in kind or cash, and converts at $137.79 a share. It avoids a debt maturity. It also adds a claim ahead of common stock. The company gave no runway guidance in the second-quarter release.

The risks

Execution comes first. The company is launching up to three drugs in a short stretch, with each needing separate field teams, patient finding and payer work. A delay on any of them would hit the plan the financing was raised for.

Second, the Attruby growth story depends on persuading cardiologists that acoramidis is better than tafamidis. The two real-world studies, one on claims data and one on health records, favor acoramidis, but both are observational, short and company-announced. No randomized head-to-head trial exists.

Third, the small-sample data. The encaleret symptom results appear to come from roughly 31 and 11 patients. The BBP-418 cardiac subgroups are 25 and 18 patients at baseline out of about 105. These support the story, but they are not what the FDA decides on.

Our read

BridgeBio is no longer a pure development bet. It has a product with a $222 million quarterly run and three FDA dates that all have priority status. That reduces the clinical risk and raises the execution risk. The financing bought time and cost a dividend.

The first real test is Nov 27. An approval of BBP-418 would be the company's second marketed drug and the first test of whether it can run more than one launch. Investors should also watch the third-quarter Attruby number, because the growth rate there matters more to the near-term story than any single study.